Veracyte, Inc.
VCYTNASDAQHealthcareDiagnostics & Research

About Veracyte

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Company Information

CEOMarc Stapley
Founded2006
IPO DateOctober 30, 2013
Employees824
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone650 243 6300
Address
6000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States

Corporate Identifiers

CIK0001384101
CUSIP92337F107
ISINUS92337F1075
EIN20-5455398
SIC8071

Leadership Team & Key Executives

Marc A. Stapley
Chief Executive Officer and Director
Rebecca Chambers
Executive Vice President and Chief Financial Officer
Dr. Phillip G. Febbo M.D.
Chief Scientific and Medical Officer
Annie McGuire
Executive Vice President, General Counsel and Chief People Officer
Dr. John Leite Ph.D.
Global Chief Commercial Officer
Dr. Keith Gligorich Ph.D.
Senior Vice President of Global Operations
Jonathan Wygant
Vice President and Chief Accounting Officer
Steven French
Senior Vice President and Chief Information Officer
Karen Possemato
Senior Vice President of Corporate Marketing, Communications and Commercial Operations
Corinne Danan
Senior Vice President